A Randomized, Double-blind Trial to Evaluate the Efficacy, Safety and Immunogenicity of MSB11022 Compared With Humira® in Subjects With Moderate to Severe Chronic Plaque Psoriasis
A Randomized, Double-blind Trial to Evaluate the Efficacy, Safety and Immunogenicity of MSB11022 Compared With Humira® in Subjects With Moderate to Severe Chronic Plaque Psoriasis
The purpose of this study was to compare the efficacy, safety and immunogenicity of MSB11022 and Humira® in adult subjects with moderate to severe chronic plaque type psoriasis.
Inclusion Criteria:
Exclusion Criteria:
Ste-Foy, Quebec G1V 4X7, Canada
Praha 8 - Liben, 180 81, Czechia
Bordeaux, Gironde 33000, France
Mérida, Yucatán 97070, Mexico
Elblag, 82-300, Poland
Torun, 87-100, Poland